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Abstract
Background: Neurodegeneration in Alzheimer's disease is associated with increased apoptosis
and parallels increased levels of amyloid beta, which can induce neuronal apoptosis. Estrogen
exposure prior to neurotoxic insult of hippocampal neurons promotes neuronal defence and
survival against neurodegenerative insults including amyloid beta. Although all underlying molecular
mechanisms of amyloid beta neurotoxicity remain undetermined, mitochondrial dysfunction,
including altered calcium homeostasis and Bcl-2 expression, are involved in neurodegenerative
vulnerability.
Results: In this study, we investigated the mechanism of 17β-estradiol-induced prevention of
amyloid beta-induced apoptosis of rat hippocampal neuronal cultures. Estradiol treatment prior to
amyloid beta exposure significantly reduced the number of apoptotic neurons and the associated
rise in resting intracellular calcium levels. Amyloid beta exposure provoked down regulation of a
key antiapoptotic protein, Bcl-2, and resulted in mitochondrial translocation of Bax, a protein
known to promote cell death, and subsequent release of cytochrome c. E2 pretreatment inhibited
the amyloid beta-induced decrease in Bcl-2 expression, translocation of Bax to the mitochondria
and subsequent release of cytochrome c. Further implicating the mitochondria as a target of
estradiol action, in vivo estradiol treatment enhanced the respiratory function of whole brain
mitochondria. In addition, estradiol pretreatment protected isolated mitochondria against calcium-
induced loss of respiratory function.
Conclusion: Therefore, we propose that estradiol pretreatment protects against amyloid beta
neurotoxicity by limiting mitochondrial dysfunction via activation of antiapoptotic mechanisms.
Background
A growing body of evidence supports the critical role of
amyloid beta peptide (Aβ)2 in Alzheimer's disease (AD)
pathogenesis. Early onset AD is associated with overpro-
duction of the 42-amino acid form of Aβ (Aβ1–42) and
Aβ1–42 is toxic to neurons in vitro and in vivo [1-3]. To
develop therapeutic strategies for reducing neuronal loss
in AD, much effort has been extended to determine the
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molecular interactions underlying Aβ-induced neurotox-
icity. Several lines of evidence suggest that calcium plays a
key role in age-related changes in the brain that lead to AD
and dementia [4-7]. Free intracellular calcium is a key acti-
vator of many signal transduction pathways of neurons,
and alterations in intracellular calcium homeostasis are
pivotal regulators of brain aging, memory and cell death
[4-6,8-11]. According to a "calcium hypothesis" of AD,
disturbances in calcium homeostasis are the proximal
cause of neurodegeneration in AD, in which calcium dys-
function augments tau hyperphosphorylation, Aβ forma-
tion and neurotoxicity [4,5,9,12].
Calcium (Ca2+) transients in neurons are largely deter-
mined by mitochondria due to their large Ca2+ capacity
[13]. Mitochondrial Ca2+ uptake is driven by the mito-
chondrial membrane potential (∆Ψm) and occurs at the
threshold of cytosolic Ca2+, followed by slow release,
leading to a net accumulation of mitochondrial calcium
([Ca2+]m) and an alteration of physiological [Ca2+]i tran-
sients [14,15]. Mitochondrial dysfunction often leads to
dysregulation of Ca2+  homeostasis and consequent
adverse downstream effects, including further damage to
mitochondria setting up the mitochondrial spiral that is
associated with multiple central nervous system disorders
[16]. During aging, especially during the development
and progression of neurodegenerative diseases, including
AD, damaged mitochondria are unable to maintain the
energy demands of the cell [17,18]. This can lead to an
increased production of free radicals, which induces the
interruption of oxidative phosphorylation, resulting in
decreased levels of ATP that are necessary for normal
energy homeostasis [16]. Apoptosis of degenerating neu-
rons occurs in association with an accumulation of abnor-
mal mitochondria in perikaryal regions and oxidative
damage to the nucleus [19]. The same pattern of mito-
chondria lesions is observed in human AD brain biopsy
samples [19]. Thus, therapeutic interventions that pro-
mote mitochondrial function could be a strategy to pre-
vent neuronal dysfunction and death.
A prevention mode of estrogen exposure can prevent neu-
rotoxicity both in vitro and in vivo [20-25]. Many of the
proximate effects of estrogen treatment that have been
associated with estrogen-induced neuroprotection con-
verge upon the mitochondria [7,26]. We have previously
shown that estrogen-induced neuroprotection is medi-
ated through regulation of calcium homeostasis [22,26].
Further, we have shown that 17β-estradiol restores cal-
cium homeostasis in neurons from middle-aged and old
rats [27]. That the estrogen-induced regulation of calcium
homeostasis is dependent upon maintenance of mito-
chondrial respiration and ∆Ψm [22] indicates a direct role
of mitochondria in the neuroprotective effects of estro-
gen.
In the present study, we investigated the mechanisms
whereby 17β-estradiol (E2) exposure can prevent Aβ-
induced neuronal apoptosis and mitochondrial function.
Results of these analyses indicate that E2 protects rat hip-
pocampal neurons against Aβ toxicity and that such pro-
tection is associated with maintenance of calcium
homeostasis, a decrease of cytochrome c release, a
decrease of Bax translocation to the mitochondria and
enhanced mitochondrial respiratory function. These data
together with previously published findings indicate that
E2 exposure prior to Aβ insult leads to a complex array of
responses that coalesce in an organized cellular strategy to
prevent loss of mitochondrial calcium homeostasis while
simultaneously promoting Bcl-2 family protein strategies
that prevent opening of the membrane permeability tran-
sition pore.
Results
17β-estradiol prevents amyloid beta-induced neuronal 
death
To determine the impact of 17β-estradiol (E2) on Aβ neu-
rotoxicity, 10 day old rat primary hippocampal neurons
with elaborate neurite networks were treated with E2 (10
ng/mL) for 48 hr prior to exposure to fibrillar Aβ1–42 (1.5
µM) for 72 hr in the continued presence of E2. The con-
centration of 10 ng/ml of E2 was used based on multiple
prior analyses indicating that this concentration induces
maximal neuroprotection and the least degree of variabil-
ity between experiments [20,26-28]. CalceinAM and
ethidium homodimer staining, which reflect neuronal
survival and death, respectively, indicated neuronal death
following 72 hr exposure to Aβ1–42 (1.5 µM) compared to
vehicle control-treated cultures (Fig. 1). Aβ1–42 exposure
significantly decreased neuronal survival (Fig. 1B) as indi-
cated by a decrease in the calcein signal (Fig. 1B; p < 0.01
as compared to control; n = 4) and an increase in the
amount of ethidium homodimer signal (Fig. 1C; p < 0.01
as compared to control; n = 4). E2 (10 ng/mL) had no
effect on neuronal survival in the absence of Aβ1–42 (Fig-
ure 1A,B &1C). Pretreatment of hippocampal neurons
with E2 (10 ng/mL) significantly reduced the amount of
Aβ1–42-induced neurotoxicity (Fig. 1A), as indicated by the
significant attenuation of the Aβ1–42-induced neuronal
death as indicated by increased Calcein fluorescence (Fig.
1B; p < 0.01 as compared to Aβ1–42 alone; n = 4) and
decreased ethidium homodimer fluorescence (Fig. 1C; p <
0.01 as compared to Aβ1–42 alone; n = 4). Following 72 hr
of Aβ exposure, neurites were thickened and beaded and
there was an increase in the number of phase bright cells,
indicative of neuronal death compared to vehicle control
and E2-treated neurons (data not shown).
To determine if E2-induced alterations in neuronal sur-
vival were mediated via regulation of apoptosis, TUNEL
staining was performed to identify apoptotic nuclei inBMC Neuroscience 2006, 7:74 http://www.biomedcentral.com/1471-2202/7/74
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17β-estradiol prevents Amyloid beta1–42-induced neurotoxicity Figure 1
17β-estradiol prevents Amyloid beta1–42-induced neurotoxicity. Primary hippocampal neurons pretreated with E2 (10 ng/mL; 48 
hr) or vehicle control were exposed to Aβ1–42 for 3 days and assessed for neuronal survival by calcein/ethidium homodimer 
staining. A, Visualization of viable (green) and dead (red) neurons. Bar = 20 µm. B-C, Fluorometer readings of calcein (live) and 
ethidium homodimer (dead) signals. (** = p < 0.01 as compared to control; ++ = p < 0.01 as compared to Aβ1–42 alone; n = 4).BMC Neuroscience 2006, 7:74 http://www.biomedcentral.com/1471-2202/7/74
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response to Aβ1–42 in the presence and absence of E2 (Fig.
2A). Primary hippocampal neurons were pretreated with
E2 (10 ng/mL) or vehicle control for 48 hr prior to Aβ1–42
(1.5 µM) exposure for 3 days in the continued presence of
E2 or vehicle control. Aβ1–42 exposure resulted in a signifi-
cant increase in the number of TUNEL-positive neurons
(Fig. 2B; p < 0.05 as compared to control; n = 4). E2 treat-
ment prior to Aβ1–42 exposure resulted in a significantly
lower percentage of TUNEL-positive neurons than
observed in response to Aβ1–42 exposure in vehicle control
treated neurons, indicating that E2-treatment significantly
reduced the amount of Aβ1–42-induced apoptosis (Fig. 2A
&2B; p < 0.05 as compared to Aβ1–42 alone; n = 4). E2
alone had no significant effect on the percentage TUNEL-
positive neurons (Fig. 2).
17β-estradiol prevents amyloid beta1–42-induced 
dysregulation of calcium homeostasis
One potential mechanism of Aβ1–42-induced neurotoxic-
ity is dysregulation of calcium homeostasis, which leads
to an increased cytosolic calcium load and can result in
neuronal dysfunction and death [4,9,27]. We have previ-
ously shown that estrogen-induced neuroprotection
against glutamate excitotoxicity is mediated via regulation
of neuronal calcium homeostasis [22] and that 17β-estra-
diol can both promote and restore calcium homeostasis
in neurons derived from middle aged and aged rat hippoc-
ampi [27]. To determine if E2-induced neuroprotection
against Aβ1–42 is likewise due to regulation of calcium
homeostasis, we conducted Fura2 calcium imaging to
assess the effect of Aβ1–42 on basal neuronal calcium loads
in the presence and absence of E2 (Fig. 3). Hippocampal
neurons were pretreated with E2 (10 ng/mL) or vehicle
control for 48 hr prior to Aβ1–42 exposure for 24 hr. Aβ1–42
exposure resulted in a significant increase in the resting
cytosolic calcium concentration (Fig. 3; p < 0.01 as com-
pared to control; n = 4). E2 pretreatment significantly
attenuated the Aβ1–42-induced rise in resting calcium con-
centration Fig. 3; p < 0.01 as compared to Aβ1–42 alone; n
= 4). E2 by itself had no significant effect on resting cal-
cium concentration (Fig. 3).
17β-estradiol prevents amyloid beta1–42-induced depletion 
of mitochondrial Bcl-2
Bcl-2 is well established as an anti-apoptotic protein in
neurons that can avert neuronal death and protect mito-
chondria against toxin-induced dysfunction [29,30]. It
has been shown that Aβ down regulates Bcl-2 in human
primary neurons [31]. Further, Bcl-2 is an estrogen-
responsive protein [7,22,32-35]. It has also been sug-
gested that Bcl-2 is involved in maintenance of cellular
calcium homeostasis [29,30]. To determine if mitochon-
drial expression of this key regulator of apoptosis was
involved in E2-induced neuroprotection, we determined
the effect of E2 and Aβ1–42 on Bcl-2 expression in the mito-
chondrial fraction of rat primary hippocampal neurons.
Neurons were pretreated with E2 (10 ng/mL) or vehicle
control for 48 hr prior to exposure to Aβ1–42 (1.5 µM) for
24 hr. Crude mitochondrial fractions were assessed for
Bcl-2 expression by Western blot analysis. Exposure to
Aβ1–42 resulted in a significant decrease (~60%) in Bcl-2
expression in the mitochondrial fraction (Fig. 4; p < 0.01
as compared to control; n = 4). As expected, E2 by itself sig-
nificantly increased (~60%) mitochondrial Bcl-2 expres-
sion (Fig. 4A; p < 0.05 as compared to control).
17β-estradiol prevents Amyloid beta1–42-induced apoptosis Figure 2
17β-estradiol prevents Amyloid beta1–42-induced apoptosis. 
Primary hippocampal neurons pretreated with E2 (10 ng/mL; 
48 hr) or vehicle control were exposed to Aβ1–42 for 3 days 
and assessed for apoptosis by TUNEL staining. A, Represent-
ative images of TUNEL positive neurons and total nuclei. Bar 
= 20 µm. B, Counts of TUNEL positive neurons normalized 
to total nuclei from 3 random fields per well are presented as 
mean ± SEM. (* = p < 0.05 as compared to control; + = p < 
0.05 as compared to Aβ1–42 alone; n = 4).
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Pretreatment of neurons with E2 completely prevented
Aβ1–42-induced decrease in mitochondrial Bcl-2 (Fig. 4; p
< 0.01 as compared to Aβ1–42 alone; p < 0.05 as compared
to control; n = 4).
17β-estradiol prevents amyloid beta1–42-induced 
translocation of Bax
Neurotoxicity resulting from apoptosis often results from
the induction of Bax translocation from the cytosol to the
mitochondria where it can mediate the release of apop-
totic factors such as cytochrome c [36-39]. To determine if
the neuroprotective effect of E2 is associated with regula-
tion of Bax translocation or cytochrome c release, primary
hippocampal neurons were pretreated with E2 (10 ng/mL)
or vehicle control for 48 hr prior to Aβ1–42 (1.5 µM) expo-
sure for 24 hr and assessed for Bax localization by Western
blot and immunocytochemical analyses.
Aβ1–42 exposure resulted in a significant increase in Bax
immunoreactivity in the mitochondrial fraction (Fig. 5; p
< 0.05 as compared to control; n = 4). E2 pretreatment sig-
nificantly attenuated the Aβ1–42-induced increase in Bax
immunoreactivity in the mitochondrial fraction (Fig. 5A;
p < 0.05 as compared to Aβ1–42 alone; n = 4). In contrast
to the mitochondrial fraction there was no change in Bax
immunoreactivity in the cytosolic fraction (Fig. 5A; n = 4).
To confirm the shift in subcellular localization of Bax, we
performed immunoflourescent staining for Bax. In con-
trol neurons, the Bax immunofluorescence signal was dif-
fuse throughout the cell body and neurites (Fig. 5B, left
panel). In Aβ1–42-treated cells the Bax immunofluores-
cence signal was punctate, consistent with a shift to mito-
chondrial localization (Fig. 5B middle panel).
Pretreatment of hippocampal neurons with E2 prevented
Aβ1–42-induced translocation of Bax, resulting in a diffuse
cytosolic staining pattern with slight areas of clustering
consistent with partial mitochondrial translocation (Fig.
5B, right panel).
17β-estradiol prevents amyloid beta1–42-induced release of 
cytochrome c
To determine the consequences of regulation of Bcl-2 and
translocation of Bax, we determined the impact of E2 pre-
17β-estradiol prevents Amyloid beta1–42-induced decline in  mitochondrial Bcl-2 expression and Bax translocation Figure 4
17β-estradiol prevents Amyloid beta1–42-induced decline in 
mitochondrial Bcl-2 expression and Bax translocation. Pri-
mary hippocampal neurons pretreated with E2 (10 ng/mL; 48 
hr) or vehicle control were exposed to Aβ1–42 for 24 hr and 
mitochondrial fractions were assessed for (A) Bcl-2 and (B) 
Bax expression by Western blot analysis. (* = p < 0.05 as 
compared to control; ** = p < 0.01 as compared to control; 
+ = p < 0.05 as compared to Aβ1–42 alone; n = 4).
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17β-estradiol prevents Amyloid beta1–42-induced rise in rest- ing calcium concentration Figure 3
17β-estradiol prevents Amyloid beta1–42-induced rise in rest-
ing calcium concentration. Primary hippocampal neurons 
pretreated with E2 (10 ng/mL; 48 hr) or vehicle control were 
exposed to Aβ1–42 for 24 hr and assessed for cytosolic cal-
cium concentration by Fura2 imaging. A. Representative 
images of Fura2 fluorescence in psuedocolor representing 
340/380 ratio. B. Quantitative changes in Fura2 340/380 ratio 
presented as means +/- S.E.M. (** = p < 0.01 as compared to 
control; ++ = p < 0.01 as compared to Aβ1–42 alone; n = 4).
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17β-estradiol prevents Amyloid beta1–42-induced Bax translocation Figure 5
17β-estradiol prevents Amyloid beta1–42-induced Bax translocation. Primary hippocampal neurons pretreated with E2 (10 ng/
mL; 48 hr) or vehicle control were exposed to Aβ1–42 for 24 hr and mitochondrial fractions were assessed for Bax expression 
by (A) Western blot analysis and (B) immunocytochemistry. The order of bands was switched to maintain a consistent treat-
ment order across all figures for presentation purposes only. All quantitation and analysis was performed unmodified images. (* 
= p < 0.05 as compared to control; ** = p < 0.01 as compared to control; + = p < 0.05 as compared to Aβ1–42 alone; n = 4).
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treatment and Aβ1–42 exposure on cytochrome C release
from mitochondria. Aβ1–42 exposure resulted in a signifi-
cant increase in cytochrome c immunoreactivity in the
cytosolic fraction (Fig. 6A; p < 0.05 as compared to con-
trol; n = 4). E2 pretreatment significantly attenuated the
Aβ1–42-induced increase in cytochrome c immunoreactiv-
ity in the cytosolic fraction while having no effect alone
(Fig. 6A; p < 0.05 as compared to Aβ1–42 alone; n = 4).
There was a corresponding significant decrease in cyto-
chrome c immunoreactivity in the mitochondrial fraction
in response to Aβ1–42 (Fig. 6A; p < 0.05 as compared to
control; n = 4) that was prevented by E2 pretreatment (Fig.
6A; p < 0.05 as compared to Aβ1–42 alone; n = 4). To con-
firm the subcellular localization of cytochrome c in our
conditions, neurons were double stained for cytochrome
c and mitochondria (Mitotracker Red CMXRos). In con-
trol neurons cytochrome c immunofluorescence (green)
exhibited a punctate staining pattern that overlapped (yel-
low) with the mitochondrial localization signal (red) (Fig.
6B). Aβ1–42 exposure resulted in a diminution of the punc-
tuate labeling of cytochrome c immunofluorescence
(green) particularly in the soma while the sparse neuritic
labeling for cytochrome C labeling remained. However,
the neuritic labeling for cytochrome C was not co-local-
ized with the mitochondrial localization signal (red) indi-
cating release of cytochrome c from the mitochondria
(Fig. 6B). The cytochrome c immunofluorescence (green)
in the E2 pretreated and Aβ1–42 exposed neurons exhibited
a punctate staining pattern that overlapped (yellow) with
the mitochondrial localization signal (red), as in the con-
trol cultures (Fig. 6B).
To determine the relationship between cytochrome c
release and Bax translocation, hippocampal neurons were
assessed for Bax and cytochrome c expression by double
immunofluorescence (Fig. 7). In control neurons the Bax
immunofluorescence signal (red) was diffuse and, as
above, the cytochrome c immunofluorescence signal
(green) was punctate (Fig. 7), consistent with cytosolic
Bax and mitochondrial cytochrome c. In Aβ1–42-treated
cells the Bax immunofluorescence signal (red) was punc-
tate, consistent with a shift to mitochondrial localization,
and, as above, the cytochrome c immunofluorescence sig-
nal (green) was diminished with a diffuse localization
(Fig. 7). Pretreatment of hippocampal neurons with E2
prevented Aβ1–42-induced translocation of Bax and release
of cytochrome C from mitochondria (Fig. 7).
17β-estradiol prevents neurotoxic-induced decline in 
mitochondria respiration
We sought to determine if the E2 treatment that prevented
the Aβ1–42-induced alterations in mitochondrial-associ-
ated proteins of primary hippocampal neurons affected
brain mitochondria in vivo. An increased mitochondrial
calcium capacity should coincide with an enhanced abil-
ity to withstand calcium load and in parallel a sustained
mitochondrial respiratory function. Whole brain mito-
chondria were isolated and assessed for respiratory func-
tion in the presence of glutamate and malate as
respiratory substrates following a 2 min challenge with
100 µM Ca2+. Oxygen consumption during State 4 (rest-
ing) respiration was not affected by the presence or
absence of calcium (100 µM) in control mitochondria
(Fig. 8A). Although mitochondrial calcium overload can
result in an uncoupling effect that would be expected to
increase State 4 respiration, this was relatively unchanged
in these experiments, consistent with previously pub-
lished results [30]. Oxygen consumption during State 3
(ADP stimulated) respiration was significantly decreased
following Ca2+ challenge in control brain mitochondria
relative to Ca2+ naive mitochondria (Fig. 8A; p < 0.05; n =
7). There was a likewise decrease (~45%) in the respira-
tory control ratio (RCR) following Ca2+ challenge of con-
trol mitochondria (Fig. 8C; p < 0.05; n = 7). RCR values
determined using atractyloside to induce State 4 respira-
tion following ADP depletion were indistinguishable
from those calculated using basal State 4 respiration read-
ings (data not shown).
To determine if E2-treatment serves a protective function
against increased calcium loads, mitochondrial respira-
tory function was assessed following a 2 min calcium
exposure in the presence of glutamate and malate. Ova-
riectomized adult rats were administered E2 (30 µg/kg in
sesame oil) or vehicle control (sesame oil) 24 hr prior to
mitochondrial isolation from whole brain tissue. Brain
mitochondria from E2-treated rats displayed significantly
greater oxygen consumption following Ca2+ challenge in
State 3 respiration and a significantly higher RCR than
mitochondria from control rats (Fig. 8C; p < 0.05; n = 7).
Further there was a smaller decrease in the RCR values fol-
lowing Ca2+ challenge in the brain mitochondria from E2-
treated rats than control (Fig. 8C; p < 0.05; n = 7).
Discussion
Neurodegenerative diseases, like Alzheimer's disease, are
associated with disruption of calcium homeostasis and
mitochondrial dysfunction leading to apoptotic events
and neuronal cell death. Previously we demonstrated that
17β-estradiol protects against age-related calcium dysreg-
ulation [27]. In this study we show that estrogen pretreat-
ment prevents amyloid beta-induced calcium
dysregulation, mitochondrial failure and resultant apop-
tosis in hippocampal neuronal cultures. These results are
consistent with previous data that demonstrate that estro-
gen is neuroprotective against Aβ-induced neurotoxicity
[21,27,40], but further the field by providing evidence for
the underlying mechanism of E2-induced neuroprotec-
tion through regulation of mitochondrial signals that ini-
tiate and activate apoptotic processes.BMC Neuroscience 2006, 7:74 http://www.biomedcentral.com/1471-2202/7/74
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17β-estradiol prevents Amyloid beta1–42-induced cytochrome c release Figure 6
17β-estradiol prevents Amyloid beta1–42-induced cytochrome c release. Primary hippocampal neurons pretreated with E2 (10 
ng/mL; 48 hr) or vehicle control were exposed to Aβ1–42 for 24 hr and assessed for cytochrome c expression by Western blot 
analysis and immunocytochemistry. A, Western blot analysis cytochrome c expression in cytosolic (right panel) and mitochon-
drial (left panel) fractions of treated neurons. B, Treated neurons were immunostained for cytochrome c expression (Green) 
and mitochondria were labeled with Mitotracker Red CMXRos (Red). Co-localization of cytochrome c with mitochondria is 
visible in the overlay image (yellow). Bar = 5 µm.
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During aging, especially during the development and pro-
gression of neurodegenerative diseases, including Alzhe-
imer's disease (AD), damaged mitochondria are unable to
maintain the energy demands of the cell. Interrupted
energy metabolism is observed in many instances of neu-
rodegeneration [16,18,19,41,42], including cerebral
ischemia and Alzheimer's disease [18], two neurological
conditions that account for the majority of all neurode-
generative conditions. Reductions in cerebral metabolic
rate often occur before the development of clinical disa-
bilities. Impairment of oxidative energy metabolism leads
to increased expression of amyloid precursor protein
(APP) [16] and to cytoskeletal disorganization, including
the appearance of epitopes associated with paired helical
filaments/tangles [43,44]. This can lead to an increased
production of free radicals, which induces the interrup-
tion of oxidative phosphorylation, resulting in decreased
levels of ATP that are necessary for normal energy home-
ostasis. Subsequently, cerebral metabolism may be una-
ble to meet the energy demands required to restore
dissipated membrane potentials, as ATP in the injured
brain is significantly reduced. Furthermore, a limited
energy supply is evident from the reductions in mitochon-
drial oxygen consumption, mitochondrial membrane
potential, and mitochondrial enzymatic activity. In this
study we demonstrated that E2 prevented the neurotoxic-
induced decline in mitochondrial respiratory function.
This is consistent with the previous reports that E2 is pro-
tective against cell death induced by energy depletion [45]
and blocks the decrease in mitochondrial membrane
17β-estradiol prevents Amyloid beta1–42-induced Bax translocation and cytochrome c release Figure 7
17β-estradiol prevents Amyloid beta1–42-induced Bax translocation and cytochrome c release. Primary hippocampal neurons 
pretreated with E2 (10 ng/mL; 48 hr) or vehicle control were exposed to Aβ1–42 for 24 hr and assessed for Bax and cytochrome 
c expression by immunocytochemistry. Treated neurons were double immunostained for Bax (Red) and cytochrome c expres-
sion (Green). Bar = 10 µm.
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17β-estradiol prevents calcium-induced damage to mitochondrial respiratory function Figure 8
17β-estradiol prevents calcium-induced damage to mitochondrial respiratory function. A. Whole brain mitochondria were iso-
lated from ovariectomized rats and assessed for mitochondrial respiration in the presence of glutamate (5 µM) and malate (5 
µM) as respiratory substrates following a 2 min challenge with 100 µM Ca2+ or buffer control. Respiratory control ratio (RCR) 
is the ratio of State 3 (ADP stimulated) respiration to State 4 (resting) respiration. (n = 7; * = p < 0.05) B. Whole brain mito-
chondria were isolated from ovariectomized rats treated with 17β-estradiol (30 µg/kg) or vehicle control for 24 hr and 
assessed for mitochondrial respiration following 2 min calcium (10 µM) exposure in the presence of glutamate (5 µM) and 
malate (5 µM) as respiratory substrates. C. Respiratory control ratio (RCR) is the ratio of State 3 (ADP stimulated) respiration 
to State 4 (resting) respiration. (n = 7; * = p < 0.05)
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potential induced by Aβ in PC12 cells [46]. Thus E2 may
be able to prevent interruption of neuronal energy metab-
olism associated with neurodegeneration and may reduce
APP expression and paired helical filament formation.
Underlying the neurodegeneration-associated mitochon-
drial dysfunction appears to be dysregulation of calcium
homeostasis. Several lines of evidence suggest that cal-
cium plays a key role in age-related changes in the brain
that lead to AD and dementia. Free intracellular calcium is
one of the most important messengers for many signal
transduction pathways of neurons, and alterations in
intracellular calcium homeostasis are critically involved in
brain aging, memory and cell death. Landfield's group
showed that altered intracellular calcium is directly corre-
lated with impaired neuronal plasticity such that elevated
intracellular calcium and frequency facilitation were neg-
atively correlated in individual old neurons within hip-
pocampal slices [47]. This finding led these investigators
to postulate that intracellular calcium is likely elevated in
old hippocampal neurons and frequency facilitation
would thus be impaired in old hippocampal neurons dur-
ing the theta frequencies associated with cognitive
processing. Consistent with this postulate are recent in
vivo  data from studies in old rats. Foy and colleagues
found that E2 suppressed the calcium-dependent induc-
tion of long-term depression in CA1 hippocampal neu-
rons of old rats [48]. A later analysis by Foster and co-
workers showed that E2 decreased the Ca2+-activated afte-
rhyperpolarization which is larger in old rats compared to
young rat CA1 neurons and is enhanced by a higher den-
sity of L-type calcium channels in the old rat neuron [49].
More recently we have shown that estrogen can reverse the
age-associated calcium dysregulation in primary neuronal
cultures obtained from the hippocampus of aged rats
[27].
According to a "calcium hypothesis" of AD, arising from
numerous preclinical in vitro studies, disturbances in cal-
cium homeostasis are the proximal cause of neurodegen-
eration in AD [9]. There is a large body of evidence from
preclinical experimental models and from human sub-
jects that alterations in calcium signalling occur during
initial phases of AD, even before the development of overt
symptoms or any obvious extracellular amyloid-beta
pathology [4]. In the current studies, we showed that E2
pretreatment prevented the Aβ-induced rise in resting cal-
cium concentration in primary hippocampal neurons, an
effect similar to the E2-mediated reduction in calcium rise
induced by excitotoxic glutamate [22,26]. More recently
we have shown that estrogen can reverse the age-associ-
ated calcium dysregulation in primary neuronal cultures
obtained from the hippocampus of aged rats [27]. A mito-
chondrial site of action for estrogen-mediated neuropro-
tection is supported by the functional mitochondria
dependence of the attenuation of the glutamate-induced
Ca2+ rise [22].
One mechanism by which estrogen may regulate mito-
chondrial calcium homeostasis and maintain energy
metabolism is via the antiapoptotic protein Bcl-2. The
magnitude of Ca2+ accumulation by mitochondria can be
altered by Bcl-2 [29,30], which is localized to the mito-
chondrial membrane and its expression has been shown
to significantly enhance mitochondrial Ca2+ sequestration
[29,30,50]. In the current studies we demonstrated that E2
increases, and prevents the Aβ-induced decrease in, the
mitochondrial expression of Bcl-2, consistent with previ-
ous reports of E2-induced increases in Bcl-2 in reproduc-
tive tissues and brain [22,32-35,51]. In addition to
increasing the magnitude of Ca2+ sequestered by mito-
chondria, Bcl-2 enhances the tolerability of mitochondria
for increased levels of [Ca2+]i that otherwise result in dissi-
pation of ∆Ψm and cell death [52]. Consistent with the
increase in mitochondrial Ca2+ load tolerability demon-
strated here, Mattson et al. showed that a supraphysiolog-
ical concentration of E2 (10  µM) can preserve ∆Ψm in
PC12 cells expressing mutant presenilin that were
exposed to Aβ [46]. We propose that by increasing [Ca2+]m
uptake capacity, and the Bcl-2-induced resistance to Ca2+-
induced respiratory inhibition, E2 prevents Bax transloca-
tion and cytochrome c release, limiting the loss of viability
initiated by neurotoxic insults.
Conclusion
In summary, we have shown that E2 provides neuropro-
tection in rat hippocampal neurons subjected to Aβ toxic-
ity and that such protection is associated with
maintenance of calcium homeostasis, a decrease of cyto-
chrome c release, a decrease of Bax translocation to the
mitochondria and enhanced mitochondrial respiratory
function. Taken together these data indicate that mecha-
nisms of estrogen-inducible neuroprotection against
degenerative insults are a function of estrogen activation
of cellular mechanisms whose ultimate outcome is pro-
motion of mitochondrial viability. Thus mitochondria are
ideal therapeutic targets of estrogen and estrogen-like sur-
rogates in brain. Further elucidation of the mitochondrial
sites of estrogen action will allow for development of
selective therapeutic agents for use in estrogen therapy for
prevention of neurodegenerative diseases.
Methods
Chemicals
Culture materials were from Gibco BRL (Rockville, MD).
Chemicals were from MP Biomed (Irvine, CA) unless oth-
erwise noted. Steroids were dissolved in ethanol and
diluted in culture medium with final ethanol concentra-
tion <0.001%. Fura2-AM, Calcein AM and ethidium
homodimer-1 were from Molecular Probes (Eugene, OR).BMC Neuroscience 2006, 7:74 http://www.biomedcentral.com/1471-2202/7/74
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Amyloid beta1–42 was from American Peptide Company
(Sunnyvale, CA).
Neuronal culture
Hippocampal neurons from embryonic day 18 (E18) rat
fetuses were cultured as previously described and gener-
ated cultures 98% neuronal in phenotype [22]. Briefly,
embryonic rat hippocampi were dissociated by passage
through fire-polish constricted Pasteur pipettes. Neurons
plated on poly-d-lysine coated coverslips (22 mm round),
chamberslides (Falcon; 4 well) or polyethylenimine
coated 6-well plates were grown in Neurobasal medium
supplemented with 5 U/ml penicillin, 5 mg/ml strepto-
mycin, and B27 supplement at 37°C in humidified 5%
CO2 atmosphere for 10–12 days prior to experimentation.
Amyliod beta-induced injury
Neurons were pretreated with 17β-estradiol (10 ng/mL)
or vehicle control for 48 hr prior to exposure to fibrillar
amyloid beta (1.5 µM) for the indicated times. Fibrillar
Aβ1–42 was prepared by solubilizing Aβ1–42 in HCL (10
mM) at a concentration of 1 mM. Aβ1–42 was diluted in
PBS to 100 µM and incubated for 72 hr at 22°C [40]. At
the beginning of each experiment Aβ1–42  was further
diluted to 1.5 µM in complete Neurobasal medium.
Neuronal survival
Cell viability was measured by calcein/ethidium
homodimer staining. Neurons were incubated in phos-
phate buffered saline (PBS) containing calcein AM (1 µM)
and ethidium homodimer-1 (2 µM) for 30 min at room
temperature. Fluorescent intensity was measured using a
dual-wavelength fluorescent plate reader (GeniosPro;
Molecular Devices) at 485/530 nm Ex/Em and 530/645
nm Ex/Em for calcein and ethidium, respectively. Data
represents percent live or dead cells normalized to control
fluorescent values. Data is presented as mean ± S.E.M.
from 4 independent experiments with 8 wells per condi-
tion per experiment. Images were captured using the Mar-
ianas imaging system with Slidebook software (Intelligent
Imaging Innovations, Inc., Santa Monica, CA) based on a
Zeiss 200 M inverted microscope.
TUNEL staining
Neurons grown on chamber slides were treated as for
Neuronal Survival above and fixed in 4% paraformalde-
hyde for 15 at room temperature and processed for
TUNEL staining by the In Situ Cell Death Detection Kit,
Fluorescein kit (Roche Applied Science; Indianapolis, IN)
according to the manufacturer's instructions. Neurons
were counterstained with DAPI to label nuclei. Three ran-
dom fields per well were captured using the Marianas
imaging system with Slidebook software (Intelligent
Imaging Innovations, Inc., Santa Monica, CA) based on a
Zeiss 200 M inverted microscope. Images were captured
from 3 wells per condition per experiment (total of 9
fields per condition). Number of TUNEL positive neurons
and number of nuclei (DAPI) were determined using
Slidebook software and percent TUNEL positive neurons
was calculated from the ratio of number of TUNEL posi-
tive neurons to number of total nuclei. Data represents the
mean ± SEM from 4 independent experiments.
Measurement of cytoplasmic Ca2+ using Fura2-AM
Hippocampal neurons grown on glass coverslips were
pretreated with E2 (10 ng/mL) or vehicle control for 48 hr
prior Aβ1–42 exposure for 24 hr. Neurons were loaded in
the dark with Fura2-AM (2 µM) in Hank's Buffered Saline
(HBS) (45 min.; 37°C). Cytosolic calcium concentrations
were determined by comparing the 340/380 ratio to a
standard curve as previously described [22]. At least 10
neurons per coverslip were assessed with at least 3 cover-
slips per condition per experiment. Data represents the
mean ± SEM from 4 independent experiments. Equal dye
loading was determined as previously described [22].
Western blot analysis
Cytosolic and mitochondrial fractions were obtained
using the Cytosol/Mitochondrial Fractionation Kit (Calbi-
ochem; Sand Diego, CA) according to the manufacturer's
instructions. Protein concentration was determined by the
BCA assay. 25 µg of total protein were loaded per well and
electorphoresed in a 2% SDS-PAGE gel. Protein was elec-
trotransfered to PVDF membranes and probed with pri-
mary antibodies to Bcl-2 (1:250; BD Transduction
Laboratories (610539); San Jose, CA), Bax (1:1000; Cell
Signaling Technology (2772); Beverly, MA) and cyto-
chrome c (1:1000; BD Transduction Laboratories
(5564333); San Jose, CA) and respective horseradish per-
oxidase (HRP)- conjugated secondary antibodies
(1:10,000; 1 hr room temperature). Porin (Mitosciences,
Eugen, OR) and Actin (Santa Cruz, Santa Cruz CA) were
used as loading controls for mitochondrial and cytosolic
fraction, respectively (Data not shown). Bands were visu-
alized with TMB peroxidase kit (Vector Laboratories) and
quantitated by scanning and densitometry with Un-Scan-
It software (Silk Scientific; Orem, UT). Data are presented
as means ± S.E.M. from 4 independent experiments.
Immunostaining
Treated neurons grown on chamberslides were fixed in
4% paaraformaldehyde for 15 at room temperature 24 hr
following Aβ exposure. For mitochondrial labeling, neu-
rons were incubated in Mitotracker Red CMXRos for 10
min at 37°C for 10 min prior to fixation. Neurons were
washed in PBS and permeabilized in PBS + 0.01% triton
X-100 for 5 min prior to incubation in primary antibody
(Bax: 1:250; Cell Signaling Technology (2772); Beverly,
MA; cytochrome c: 1:250; Pharmingen (556432); San
Jose, CA) for 2 hr at room temperature. Antibody-antigenBMC Neuroscience 2006, 7:74 http://www.biomedcentral.com/1471-2202/7/74
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complexes were visualized by incubating in FITC (1:250;
Vector Laboratories; Burlingame, CA)- or CY3 (1:1000;
Amersham; Piscataway, NJ)-conjugated secondary anti-
bodies for 45 min at room temperature, coverslipping
with DAPI containing mounting medium (Vector Labora-
tories; Burlingame, CA) and capturing images using the
Marianas imaging system with Slidebook software (Intel-
ligent Imaging Innovations, Inc., Santa Monica, CA).
Mitochondrial isolation
Adult (4–6 months old) female ovariectomized Sprague-
Dawley rats were injected subcutaneously with 17b-estra-
diol (30 µg/kg) in sesame oil 2 weeks following surgery.
24 hr later, rats were sacrificed and whole brain tissue was
homogenized in mitochondrial isolation buffer (0.32 M
sucrose, 1 mM EDTA and 10 mM Tris; pH 7.4). Homoge-
nates were centrifuged at 1,330 × g for 5 min at 4°C. Pel-
lets were re-homogenized and centrifuged. The two
postnuclear supernantants were combined and centri-
fuged at 21,200 × g for 10 min at 4°C. The resulting crude
mitochondrial pellets were resuspended in 15% Percoll
and layered over a 23%/40% discontinuous Percoll gradi-
ent and centrifuged at 27, 000 × g for 10 min at 4°C. The
fraction accumulating at the 23%/40% interface was col-
lected and diluted 1:4 with isolation buffer and centri-
fuged at 16,000 × g for 10 min at 4°C.
The pellet was transferred to a 1.5 ml tube centrifuged at
7,300 × g for 10 min at 4°C. The pellet will be resus-
pended in 40 µL isolation buffer. Protein concentration
will be determined by the BCA assay. Mitochondrial integ-
rity was assessed assessing cytochrome c oxidase activity
(Cytochrome c oxidase activity kit, Sigma) in intact and
lysed mitochondrial samples. Cytochrome c oxidase in
inaccessible in intact mitochondria and high activity in
these samples relative to total activity (lysed samples)
indicates poor mitochondrial integrity.
Measurement of respiration in mitochondria isolated from 
rat brains
Aliquots of mitochondria (1 mg/mL) were used in meas-
urements of respiratory activity using a Clark-type oxygen
electrode (Hansatech Oxygraph) as previously described.
Oxygen electrode buffer (130 mM KCl, 2 mM KH2PO4, 3
mM HEPES, 2 mM MgCl2, 1 mM EGTA) was incubated for
1 min in a magnetically stirred chamber at 28°C. The res-
piratory substrates, glutamate (5 mM) and malate (2.5
mM), were added followed by the isolated mitochondria
(100  µg). Basal respiration was first measured in the
absence of ADP for 1 min, followed by Ca2+ (100 µM) or
equivalent volume of buffer for an additional 2 min. Sub-
sequently, State 3 respiration was measured in the pres-
ence of ADP, by addition of 20 mL ADP (0.027 M in 0.067
M NaPO4) to determine the maximal rate of coupled ATP
synthesis. Then State 4 respiration was induced by addi-
tion of the adenine nucleotide translocator inhibitor
atractyloside (50 µM). The respiratory control ratio was
calculated using the ratio of State 3 to State 4 respiratory
rates.
Statistics
Statistically significant differences were determined by
one-way ANOVA followed by Student-Neuman Keuls
post hoc analysis.
Abbreviations
The abbreviations used are: Aβ, amyloid beta; AD, Alzhe-
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chondrial calcium concentration; [Ca2+]i, cytosolic cal-
cium concentration; E2, 17β-estradiol; APP, amyloid
precursor protein.
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